

Apr 14, 2025

Version 1

Infection related adverse events in adult patients with severe asthma treated with Tezepelumab, a systematic review and meta-analysis V.1

DOI

<https://dx.doi.org/10.17504/protocols.io.3byl4zkn8vo5/v1>

Felix Reyes¹, Tanvi Tiwari², Eduardo Saadi Neto³

¹Northwest Medical Center; ²Department of Hospital Medicine, Meritus Medical center, Hagerstown, Maryland;

³School of Medicine, Univalle, Cochabamba, Bolivia.



Felix Reyes

Northwest Medical Center

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.3byl4zkn8vo5/v1>

Protocol Citation: Felix Reyes, Tanvi Tiwari, Eduardo Saadi Neto 2025. Infection related adverse events in adult patients with severe asthma treated with Tezepelumab, a systematic review and meta-analysis. **protocols.io**

<https://dx.doi.org/10.17504/protocols.io.3byl4zkn8vo5/v1>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited



Protocol status: Working

We use this protocol and it's working

Created: April 13, 2025

Last Modified: April 14, 2025

Protocol Integer ID: 126641

Keywords: Severe Asthma, Tezepelumab, Adverse drug reactions, chronic airway inflammation, patients with severe asthma, severe asthma, analysis asthma, airway inflammation, therapy with tezepelumab, treatment of severe asthma, uncontrolled asthma, thymic stromal lymphopoietin, asthma, chronic respiratory disease, key cytokine, tezepelumab, antibody, monoclonal antibody, risk of infection, several infection, lung function, adverse events in adult patient

Abstract

Asthma is a chronic respiratory disease with different phenotypes that are characterized by chronic airway inflammation. Severe asthma is a subset of difficult-to-treat asthma defined as uncontrolled asthma despite adherence to treatment with maximal optimized high-doses of ICS-LABA. Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key cytokine involved in airway inflammation. It is approved for the treatment of severe asthma to reduce exacerbations and improve lung function. TSLP plays a role in response to several infections. Prior meta-analyses have focused on determining safety and efficacy. In these studies infections were only analyzed as secondary outcomes. We aim to identify the risk of infection in patients with severe asthma undergoing therapy with Tezepelumab.

Search Strategy

- 1 ("Severe asthma" OR "uncontrolled asthma") AND (tezepelumab OR "anti thymic stromal lymphopoietin" OR "anti-TSLP" OR the spine) AND ("randomized controlled trial"[PT] OR "controlled clinical trial"[Publication Type] OR "randomized"[Title/Abstract] OR "placebo"[Title/Abstract] OR "drug therapy"[MeSH Subheading] OR ("randomly"[Title/Abstract] OR "trial"[Title/Abstract] OR "groups"[Title/Abstract])) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])

Cochrane search:

("Severe asthma" OR "uncontrolled asthma") AND (tezepelumab OR "anti thymic stromal lymphopoietin" OR "anti-TSLP" OR tezspire)

Eligibility Criteria

- 2 We will include studies evaluating patients with severe asthma despite optimal therapy, irrespective of age, sex, country, and ethnic group. Randomized controlled trial the study must compare Tezepelumab to placebo.

We will exclude studies involving patients with documented Asthma-COPD Overlap syndrome, other severe pulmonary diseases and children (under 18 years of age). If a study reports active smokers, we will exclude active smokers from analysis.

We excluded non-human studies and in vitro research, editorials, conference proceedings, commentaries, expert opinion, reviews, studies without original data, non-English publications, and duplicate publications.

Intervention(s), exposure(s)

- 3 Therapy with tezepelumab

Comparator/control



4 Placebo

Types of study to be included

5 Randomized control trial

Context

6 We will include only studies that report on any of the outcomes of interest, as reported below. We will also collect data on subgroups of sex, age, race, pulmonary function test, eosinophil counts, Quality of life scores, and frequency of exacerbations.

Main outcome(s)

7 We will extract data for a pooled analysis on the following outcomes: (1) Pneumonia (Lower respiratory tract infection); (2) Bronchitis; (3) Nasopharyngitis; (4) Upper Respiratory Tract Infections; (5) Other non-respiratory infectious adverse events

Measures of effect: Hazards ratio, and Odds ratio

Study Records

8 All protocol amendments, data extraction updates, and decisions regarding inclusion/exclusion will be logged in a version-controlled document to ensure auditability. The review will be conducted in accordance with the PRISMA and MOOSE guidelines for systematic reviews and meta-analyses.

Data Management

9 All data related to this systematic review and meta-analysis will be collected, managed, and stored in accordance with established methodological guidelines and principles of transparency and reproducibility. All extracted data will be stored securely in password-protected Excel spreadsheets.

Only authorized members of the review team will have access to the data files. Regular backups will be created to prevent data loss.

Selection Process

- 10 Titles and abstracts identified through the search strategy will be screened independently by two reviewers (FR and TT). Discrepancies between reviewers will be resolved through adjudication by a third, independent reviewer (ESN)

Data Collection process

11 Data Extraction

Data on each of the outcomes described will be collected.

Data will be extracted independently by two team members. If further information is required, authors from the original article will be contacted to obtain data not available in published reports.

A standardized data extraction form will be developed and pilot tested. The following data will be extracted from each included study:

- Study

Characteristics: First author, publication year, country, study design, trial registration (if applicable), funding sources, and conflict of interest disclosures.

- Participant

Characteristics: Sample size, mean age, gender distribution, baseline asthma severity, inclusion/exclusion criteria.

- Intervention

Details: Dose, duration, and route of Tezepelumab administration; co-interventions; standard therapy components.

- Outcomes:

Type and number of adverse events (including total AEs and specific types like infections), definitions used, follow-up duration, and method of adverse event reporting.

In addition, the following baseline characteristics will be collected: (1) race distribution; (2)

proportion of patients with severe persistent asthma with eosinophilia; (3) proportion of patients with severe persistent asthma without eosinophilia; (4) Quality of life scores; (5) comorbidities; and (6) follow-up in months. The data will be extracted and recorded on an Excel template by two authors: FR and TT.

Risk of Bias Assessment

- 12 We will use the Cochrane Collaboration's tool for assessing risk of bias in randomized trials for quality assessment of individual randomized studies.

Strategy for data synthesis

- 13 The systematic review and meta-analysis will be performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement guidelines.
- A meta-analysis will be performed if ≥ 2 studies report the same outcome (e.g., adverse events or infections) in a comparable way. We will extract the data from individual studies using hazard ratios (HR) to preserve time-to-event data from individual studies. Effects for binary endpoints (e.g., incidence of adverse events, infections) will be compared using pooled HR or odds-ratios (OR) with 95% confidence intervals. Weighted mean differences will be used to pool continuous outcomes. Heterogeneity will be evaluated with Cochran Q test and I^2 statistics; p values inferior to 0.10 and $I^2 > 25\%$ will be considered significant for heterogeneity. The decision to use either a random-effect or fixed-effect model will be made after a critical appraisal of all included studies. Review Manager 5.4 (Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) will be used for statistical analysis

Analysis of subgroups or subsets

- 14 We will extract data and perform sub-analyses in the following subgroups: (1) male; (2) female; (3) age ≥ 65 years old; (4) age < 65 years old; (5) by duration of follow up (less than 6 months and greater than 6 months); (7) By type of adverse event (e.g: infections vs general Adverse events)

Meta-bias Assessment



15 If ≥ 10 studies are included in a meta-analysis, publication bias will be assessed via:

- Visual inspection of funnel plots
- Egger's regression test for small-study effects

Keywords

16 Severe Asthma
Tezepelumab
Adverse drug reactions

Language

17 English

Conflicts of Interest

18 None

Funding

19 None

Protocol references

- Qin J, Wang G, Han D. Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials. *J Asthma*. 2025 Jan;62(1):4-13. doi: 10.1080/02770903.2024.2385973. Epub 2024 Aug 2. PMID: 39067012.
- Shaban Abdelgalil M, Ahmed Elrashedy A, Awad AK, Reda Gad E, Ali MM, Abdelmoez Farahat R, Hassan Shawki B, Abd-ElGawad M. Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. *Sci Rep*. 2022 Dec 3;12(1):20905. doi: 10.1038/s41598-022-24763-9. PMID: 36463281; PMCID: PMC9719466.
- Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10. Erratum in: *Lancet Respir Med*. 2021 Nov;9(11):e106. doi: 10.1016/S2213-2600(21)00446-X. PMID: 34256031.
- Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. *N Engl J Med*. 2021 May 13;384(19):1800-1809. doi: 10.1056/NEJMoa2034975. PMID: 33979488.
- Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma. *N Engl J Med*. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. Erratum in: *N Engl J Med*. 2019 May 23;380(21):2082. doi: 10.1056/NEJMr180026. PMID: 28877011.
- Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Safapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. *Lancet Respir Med*. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Erratum in: *Lancet Respir Med*. 2022 Jul;10(7):e72. doi: 10.1016/S2213-2600(22)00128-X. PMID: 35364018.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71.